KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to 0.7.

  • Vertex Pharmaceuticals' Equity Ratio fell 88.69% to 0.7 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.7, marking a year-over-year decrease of 88.69%. This contributed to the annual value of 0.73 for FY2024, which is 584.36% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Equity Ratio of 0.7 as of Q3 2025, which was down 88.69% from 0.71 recorded in Q2 2025.
  • Vertex Pharmaceuticals' Equity Ratio's 5-year high stood at 0.78 during Q3 2022, with a 5-year trough of 0.7 in Q3 2025.
  • For the 5-year period, Vertex Pharmaceuticals' Equity Ratio averaged around 0.75, with its median value being 0.76 (2021).
  • In the last 5 years, Vertex Pharmaceuticals' Equity Ratio skyrocketed by 494.9% in 2021 and then tumbled by 752.84% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Equity Ratio stood at 0.75 in 2021, then grew by 1.94% to 0.77 in 2022, then grew by 0.9% to 0.77 in 2023, then decreased by 5.84% to 0.73 in 2024, then decreased by 4.35% to 0.7 in 2025.
  • Its Equity Ratio was 0.7 in Q3 2025, compared to 0.71 in Q2 2025 and 0.72 in Q1 2025.